Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatmentReview Published on 2021-11-182022-10-31 Journal: The Egyptian Heart Journal [Category] COVID-19, [키워드] addition administration Adverse reaction Arrhytmia Cardiac arrhythmia cardiac arrhythmias cardiac damage cardiac electrophysiology Cardiac risk cardiovascular COVID-19 death drug interaction forms increased risk medication Pandemia Patient pharmacologic agent pharmacological agent reduce risk severe COVID-19 Severe COVID-19 Infection syndrome Therapeutic treatment treat Treatment Virology [DOI] 10.1186/s43044-021-00228-8 PMC 바로가기 [Article Type] Review
Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort StudyArticle Published on 2021-11-122022-10-30 Journal: Journal of Personalized Medicine [Category] COVID-19, [키워드] chronic conditions chronic obstructive clinically COPD COVID-19 COVID-19 patients determine diabetes disease drug drug interaction greater Health healthcare administration healthcare costs hierarchical conditions category (HCC) Hospitalization Hospitalized hyperlipidemia hypertension identify indicate Interaction interactions Length Length of stay likelihood LOS Medicare medication management member moderate outcome Patient patients hospitalized pharmacogenetic pharmacogenomics PIP precision medicine Probability pulmonary disease reduce risk risk adjustment factor (RAF) severely ill patients significantly with COVID-19 [DOI] 10.3390/jpm11111192 PMC 바로가기 [Article Type] Article
Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged TreatmentsReview Published on 2021-11-082022-10-04 Journal: International Journal of Environmental Research an [Category] MERS, SARS, 신약개발, [키워드] ADRS Adverse drug reaction applied Asthma biological pathway chronic obstructive Clinical sign clinics COPD coronavirus disease COVID-19 drug drug interaction Drug interactions Drug-drug interactions Evidence healthcare personnel Healthcare provider healthcare providers Healthcare system Hospitalization lack mechanisms medication nursing personnel outcome Patient pharmacological pharmacological agents Physicians protocol pulmonary disease recognize respiratory Respiratory disease respiratory diseases SARS-CoV-2 the disease therapeutic Till treated Treatment [DOI] 10.3390/ijerph182111711 PMC 바로가기 [Article Type] Review
Immunosuppressant Management in Renal Transplant Patients with COVID-19Review Article Published on 2021-10-142022-10-27 Journal: BioMed Research International [Category] COVID-19, MERS, SARS, [키워드] Comorbidity coronavirus disease COVID-19 drug interaction Host Immunocompromised Immunosuppressant immunosuppressed patients Immunosuppression immunosuppressive agent Immunosuppressive treatment Infection KDR kidney knowledge management pandemic Potential potential risk recipient recipients risk Side effects Transplant with COVID-19 [DOI] 10.1155/2021/9318725 PMC 바로가기 [Article Type] Review Article
Immunosuppressant Management in Renal Transplant Patients with COVID-19Review Article Published on 2021-10-142022-10-27 Journal: BioMed Research International [Category] [키워드] Comorbidity coronavirus disease COVID-19 drug interaction Host Immunocompromised Immunosuppressant immunosuppressed patients Immunosuppression immunosuppressive agent Immunosuppressive treatment Infection KDR kidney knowledge management pandemic Potential potential risk recipient recipients risk Side effects Transplant with COVID-19 [DOI] 10.1155/2021/9318725 PMC 바로가기 [Article Type] Review Article
Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19Review Published on 2021-09-232022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] Adverse adverse event adverse events alteration approved authorization Baricitinib Biological agent Case report clinical trial common adverse event COVID-19 drug drug interaction effective drug Emergency hospitalized patients immune dysregulation Infection Inflammatory inhibit kidneys Liver function mechanism metabolic pathway moderate-to-severe COVID-19 MONITOR monoclonal antibody pathogenic pathway Patient Pharmacology Remdesivir reported risk risk factor sarilumab Serious Adverse Event Surveillance Thromboembolism Tocilizumab Toxicity Treatment Treatment strategies [DOI] 10.3390/ph14100955 PMC 바로가기 [Article Type] Review
Long-Term Neurological Impact of COVID-19Internal Medicine Published on 2021-09-202022-10-31 Journal: Cureus [Category] COVID-19, [키워드] Anosmia Brain Care carried Central nervous system Clinical management clinician cns disorders complicate complications coronavirus disease COVID-19 discharged disease disorders drug interaction Effect enrolled Enrollment females Follow-up headache highlight hospital Impact include increased risk Inflammatory Insomnia Loss of Smell male management medication neurologic neurological Neurological disorder neurological outcomes Neurological symptoms participant Patient patients with COVID-19 Potential recent reported Research Respiratory system sars-cov-2 (severe acute respiratory syndrome coronavirus -2) sense of smell Spread stroke Symptom treat [DOI] 10.7759/cureus.18131 PMC 바로가기 [Article Type] Internal Medicine
Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In VitroArticle Published on 2021-09-032022-10-28 Journal: Pharmaceutics [Category] COVID-19, [키워드] activated activating ADK analyzed Antiviral antiviral activity antiviral drug Antiviral effect Antiviral treatment approach Calu-3 cell circulating SARS-CoV-2 variant combination therapy combined treatment Culture drug interaction Drug repurposing Effect Enzymes expressed Fluoxetine GS-441524 in vitro kinase metabolite nucleoside nucleoside GS-441524 offer patients with COVID-19 plasma Remdesivir reported Safe SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 pandemic synergistic synergy Therapeutic treatment tissues Treatment [DOI] 10.3390/pharmaceutics13091400 PMC 바로가기 [Article Type] Article
Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation studyCOVID-19 용도 변경 약물을 Medicare 및 상업적으로 보험에 가입된 환자의 약물 요법에 가상으로 추가하여 약물 부작용 위험 평가: 약물 안전성 시뮬레이션 연구Observational Study Published on 2021-09-012022-09-11 Journal: Clinical and translational science [Category] MERS, 신약개발, 임상, 치료제, [키워드] added addition ADE ADEs Adverse age Analysis approved Azithromycin baseline blueprint calculate caused Chloroquine clinical trials conducted coronavirus disease Coronavirus disease 2019 COVID-19 driven by drug drug interaction drug regimen drug regimens drugs event fexofenadine greater groups Health Health Insurance Hydroxychloroquine increase in increased risk indications Intervention Long Long QT syndrome Lopinavir Lopinavir/ritonavir median Medicare medication medication risk negative control Patient performed positive Repurposed drug Repurposed drugs risk Ritonavir subject terfenadine Treatment were used [DOI] 10.1111/cts.13025 PMC 바로가기 [Article Type] Observational Study
Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital프랑스 교육 병원에서 COVID-19 전염병 위기 및 약제 개입 동안 로피나비르/리토나비르, 하이드록시클로로퀸 및 아지트로마이신 처방 관행Article Published on 2021-09-012022-09-11 Journal: European Journal of Hospital Pharmacy [Category] 치료제, [키워드] accompanied adjusted Adverse reactions aims analysed Analysis Azithromycin Care carried Combination COVID-19 epidemic decrease demonstrated disappearance dose drug interaction Drug interactions drug misuse drug-related side effects and adverse reactions electronic medical records evaluate Evidence-based medicine excluded followed by France French Health Health care hospital Hydroxychloroquine increase in Inpatients intensive care unit intensive care units Lopinavir Lopinavir/ritonavir medication observational study Patient patients with COVID-19 performed pharmaceutical intervention Pharmaceutical interventions pharmacy service physician prescribing Prescriptions primary endpoint problems Quality of Health Care reaction regimen retrospective Ritonavir Side effect Side effects study period synergy Treatment university university hospital [DOI] 10.1136/ejhpharm-2020-002449 PMC 바로가기 [Article Type] Article